Schizophrenia
Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study
by Leslie Citrome, MD, MPH; Stephanie S. O’Malley, PhD; David McDonnell, MD; Ying Jiang, PhD; Adam C. Simmons, MPH; Mark P. Berry; and Lauren E. DiPetrillo, PhD Dr. Citrome is with the Department of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York. Dr. O’Malley is with the Department of Psychiatry […]
Validation of the Russian Version of the Positive and Negative Syndrome Scale (PANSS-Ru) and Normative Data
by Evgenia Ivanova, PhD; Anzalee Khan, PhD; Lora Liharska, MS; Alexander Reznik, MD, PhD; Sergey Kuzmin, MD; Olga Kushnir, MD, PhD; Alexey Agarkov, MD, PhD; Nikolay Bokhan, MD, PhD; Tatiana Pogorelova, MD, PhD; Olga Khomenko, MD; Ksenia Chernysheva, MD, PhD; Margarita Morozova, MD, PhD; George Rupchev, PhD; Taisia Lepilkina, PhD; Alexander Ozornin, MD, PhD; Nina […]
Transition from Obsession to Delusion in Schizo-obsessive Disorder: A Case Report and Literature Overview
By Estevão Scotti-Muzzi, MD, MS, and Osvaldo Luis Saide, MD, PhD Drs. Scotti-Muzzi and Saide are with the Psychiatry Unit, Pedro Ernesto University Hospital, State University of Rio de Janeiro, Brazil. Funding: No funding was provided. Disclosures: The authors have no conflicts of interest relevant to the content of this article. Abstract: Schizo-obsessive disorder has been […]
Pimavanserin: A Novel Drug Approved to Treat Parkinson’s Disease Psychosis
by Amanda K. Kitten, PharmD; Sarah A. Hallowell, PharmD; Stephen Saklad, PharmD, BCPP; and Kirk E. Evoy, PharmD, BCACP, BC-ADM, CTTS Drs. Kitten, Hallowell, Saklad, and Evoy are with the College of Pharmacy, The University of Texas at Austin in Austin, Texas. Innov Clin Neurosci. 2017;15(1–2):16–22 FUNDING: The authors received no funding for the development […]
Letter to the editor: Acute schizophrenia-like psychotic disorder: a critical appraisal of its diagnostic validity through a case series
Dear Editor: In the 10th edition of the International Classification of Diseases (ICD-10) the category “acute and transient psychotic disorder” (ATPD; F23) was introduced, grouping several psychotic conditions that were originally described as separate syndromes.[1] This disorder is characterized by an acute onset of psychotic symptomatology (less than 2 weeks in duration), which is often […]
The 30th Anniversary of PANSS Special Edition
Dear Colleagues: Thirty years ago, the Positive and Negative Syndrome Scale (PANSS) was developed and published by Stanley Kay, Abraham Fiszbein, and Lewis Opler to identify the presence and severity of psychopathology symptoms in patients with psychotic disorders, with the objective of measuring patient characteristics and evaluating change over time using 30 symptoms rated on […]
Precursors to the PANSS: The BPRS and its progenitors
by Nina R. Schooler, PhD Dr. Schooler is Professor of Psychiatry at SUNY Downstate Medical Center in Brooklyn, New York. Funding: No funding was provided for this article. Disclosures: The author has no financial conflicts relevant to the content of this article. Abstract: The systematic assessment of signs and symptoms of psychopathology has roots that […]
A Developmental History of the Positive and Negative Syndrome Scale (PANSS)
by Stacy Liechti, PhD; Gianna Capodilupo, MA; Douglas J. Opler, MD; Mark Opler, PhD, MPH; and Lawrence H. Yang, PhD Dr. Liechti is Lead Research Consultant at the PANSS Institute in New York, New York. Ms. Capodilupo is Research Assistant at MedAvante-ProPhase in New York, New York. Dr. D. Opler is Assistant Professor in the […]
Using the Positive and Negative Syndrome Scale (PANSS) to Define Different Domains of Negative Symptoms: Prediction of Everyday Functioning by Impairments in Emotional Expression and Emotional Experience
by Philip D. Harvey, PhD; Anzalee Khan, PhD; and Richard S. E. Keefe, PhD Dr. Harvey is Professor of Psychiatry and Behavioral Sciences at University of Miami School of Medicine in Miami, Florida. Dr. Khan is Senior Biostatistician at NeuroCog Trials and holds an appointment in the Psychopharmacology Research Program at the Nathan S. Kline […]
Insight and Treatment Outcomes in Schizophrenia: Post-hoc Analysis of a Long-term, Double-blind Study Comparing Lurasidone and Quetiapine XR
by Philip D. Harvey, PhD; Cynthia O. Siu, PhD; and Antony D. Loebel, MD Dr. Harvey is with the University of Miami Miller School of Medicine in Miami, Florida, and the Research Service of the Bruce W. Carter VA Medical Center in Miami, Florida. Dr. Siu is with COS and Associates Ltd. in Central District, […]
